Editas Medicine, Inc.
Editas Medicine, Inc. (EDIT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99 2 editasmedicinepressrelease.htm EX-99 Document Exhibit 99.1 Editas Medicine Announces Second Quarter 2026 Results and Business Updates EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or gre
Editas Medicine, Inc. (EDIT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. edit-20260617 0001650664 FALSE 0001650664 2026-06-17 2026-06-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________________________________________________________________ FORM 8-K _____________________________________________
O'Neill Gilmore Neil (CEO) sold 15,380 shares of Editas Medicine, Inc. (EDIT) at $2.70 on 2026-06-03 under a Rule 10b5-1 trading plan.
Over the past 7 days, alphai's AI scored 1 news story mentioning EDIT (Editas Medicine, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent EDIT coverage spans financial news, insider activity and earnings.
In the last 30 days, EDIT insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($15K). The most active reporter was Parison Amy, SVP, Chief Financial Officer, with 1 filing. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
Near-term catalysts are the Australia CTN submission and the next EDIT-401 data update, supported by an extended cash runway into 2H 2028 after financing.
Routine shareholder-meeting outcomes; no new operational or financial guidance disclosed.
Insider selling is a modest, mostly non-fundamental signal given the stated pre-arranged 10b5-1 plan; near-term impact is likely limited.
Likely low fundamental signal because it’s an open-market sale executed under a pre-arranged 10b5-1 plan.
Advancing a lead asset into first-in-human is a major development milestone that can reset risk/reward.
alphai scores every news story that mentions EDIT with an AI model for sentiment and relevance, and aggregates insider trades from Editas Medicine, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Editas Medicine, Inc. (EDIT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99 2 editasmedicinepressrelease.htm EX-99 Document Exhibit 99.1 Editas Medicine Announces Second Quarter 2026 Results and Business Updates EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or gre
4 min readEditas Medicine, Inc. (EDIT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. edit-20260617 0001650664 FALSE 0001650664 2026-06-17 2026-06-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________________________________________________________________ FORM 8-K _____________________________________________
2 min readO'Neill Gilmore Neil (CEO) sold 15,380 shares of Editas Medicine, Inc. (EDIT) at $2.70 on 2026-06-03 under a Rule 10b5-1 trading plan.
1 min readBurkly Linda (EVP, CHIEF SCIENTIFIC OFFICER) sold 731 shares of Editas Medicine, Inc. (EDIT) at $2.70 on 2026-06-03 under a Rule 10b5-1 trading plan.
1 min readBiotech stocks rose on varied catalysts. Q32 Bio (QTTB) jumped 85% after a $55M private placement at $8.00/share; topline SIGNAL-AA Phase 2a Part B data are expected mid-2026. Soligenix (SNGX) gained 69% as it evaluates ThermoVax for Bundibugyo Ebola. Guardant (GH) rose 6% after ACS added its Shield blood test to updated colorectal screening guidelines; Q1 revenue was $301.7M (+48%).
6 min readEditas Medicine (NASDAQ:EDIT) saw unusually heavy options activity Wednesday, with investors buying 2,160 call options, up about 245% versus average daily volume. Shares rose to $3.77 midday. The article also cites May 5 earnings: EPS of -$0.26 vs -$0.30 expected, revenue $2.83M vs $6.37M, and notes multiple analyst price targets.
4 min readEditas Medicine reported preclinical results for EDIT-401, an in vivo gene-editing system targeting the LDLR gene to lower LDL-C. In non-human primates, it showed about a 90% mean reduction in LDL-C and roughly 90% reductions in Lp(a) and ApoB, with correlated biomarker changes. GLP toxicology is ongoing with interim tolerability and no liver histopathology. The company plans an HeFH patient trial later this year and an IND filing after a successful FDA pre-IND meeting; shares fell on the news.
4 min readEditas Medicine Inc. (EDIT) reported a first-quarter loss of $25 million, or 26 cents per share, which exceeded Wall Street expectations. However, the genome editing company's revenue of $2.8 million for the period fell short of analysts' forecasts. This financial snapshot highlights Editas's mixed performance in its latest earnings report.
2 min readImage source: The Motley Fool.Wednesday, August 7, 2024 at 12:03 p.m. ETNeed a quote from a Motley Fool analyst? Email pr@fool.comContinue reading ...
5 min readGenomics gains momentum as EDIT, SANA, and PACB emerge as standout picks amid rapid advances in sequencing and gene editing.
3 min read
